|
Status |
Public on Jul 16, 2022 |
Title |
Breast Cancer 192 |
Sample type |
RNA |
|
|
Source name |
Breast tumor
|
Organism |
Homo sapiens |
Characteristics |
filename: A1764-073 plate_pos: G1 subject_id: 192 crna_conc_ng_per_ul: 1026 ratio_260_280: 2.33 ratio_260_230: 2.67 conc_ug_per_ul: 1.026 final_vol_ul_1: 22 crna_yield_ug: 22.572 crna_used_ug: 4 vol_crna_used_ul: 3.89863547758285 final_vol_ul_2: 22.5 rnase_free_water_ul: 18.6013645224172 batch: Batch1 cdna_conc_ng_per_ul: NA cdna_yield_ug: NA cdna_used_ug: NA vol_cdna_used_ul: NA dataset: FinHER
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA was extracted from FFPE tumor tissue according to the method described in Bohmann et al, Clinical Chemistry 2009
|
Label |
biotin
|
Label protocol |
Biotinylated cRNA was prepared according to Affymetrix's standard protocols
|
|
|
Hybridization protocol |
Hybridization was done according to Affymetrix's standard protocols for 96 array plate. The GeneTitan Hybridization, Wash and Stain kit for 3' IVT arrays was used for preparing hybridization mixes
|
Scan protocol |
96 array plates were scanned using Affymetriix's automated GeneTitan system according to the manufacturer's instructions
|
Description |
Biotinylated cRNA was prepared according to Affymetrix's standard protocols
|
Data processing |
The probe level intensities were background adjusted using the Robust multi-array analysis (RMA) method followed by quantile normalization as impletemented in the R/Bioconductor package affy. Probe level annotations were obtained from Affymetrix’s website. In particular, we used release 32 of the NetAffx annotation files.
|
|
|
Submission date |
Jun 16, 2013 |
Last update date |
Jan 10, 2024 |
Contact name |
Christos Sotiriou |
E-mail(s) |
christos.sotiriou@hubruxelles.be
|
Phone |
+32 2 541 34 57
|
Organization name |
Institut Jules Bordet – Université Libre de Bruxelles (ULB)
|
Lab |
Breast Cancer Translational Research Laboratory J.C. Heuson (ULB 290)
|
Street address |
Rue Meylemeersch 90
|
City |
Brussels |
ZIP/Postal code |
1070 |
Country |
Belgium |
|
|
Platform ID |
GPL13667 |
Series (1) |
GSE47994 |
Tumor-infiltrating lymphocytes, prognosis and trastuzumab benefit in early-stage breast cancer patients from the FinHER trial |
|